Skip to content
PubMed This is a summary of 12 peer-reviewed journal articles Updated
Pediatric Hematology

Daily Management and Standard of Care Treatment

At a Glance

Daily management of JAGN1 severe congenital neutropenia centers on individualized G-CSF treatment, prompt infection and fever plans, meticulous dental care, and regular monitoring of blood counts, bone marrow, growth, and spleen size.

Managing JAGN1 severe congenital neutropenia (SCN) on a daily basis is a commitment to proactive protection. Because the immune system’s “first responders” are low or dysfunctional, the standard of care focuses on boosting those cell counts where possible and guarding the body’s most vulnerable entry points, such as the mouth and skin [1][2].

The Role of G-CSF Therapy

The primary medical treatment for SCN is G-CSF (granulocyte colony-stimulating factor), a medicine given as a daily injection under the skin [1]. It acts as a signal to the bone marrow to produce more neutrophils.

However, parents of children with JAGN1-SCN should be aware of a specific challenge: low responsiveness.

  • The “Low Responder” Phenomenon: While many other types of SCN respond well to low doses of G-CSF, children with JAGN1 mutations often require much higher doses to reach a safe Absolute Neutrophil Count (ANC) [3][4].
  • Response Limits: In some JAGN1 cases, the bone marrow may not respond adequately even to high doses of G-CSF [5]. Dose, schedule, and response criteria vary; clinicians generally balance ANC, infection frequency, marrow findings, adverse effects, and the lowest effective dose. If your child continues to have serious infections despite receiving optimized doses, your medical team may discuss transitioning from G-CSF to a bone marrow transplant (HSCT) [3][4].
  • Monitoring: The goal is individualized based on your child’s infection history and tolerance [6].

Prophylactic Medications

To “back up” the immune system, doctors sometimes consider prophylactic (preventative) medications, though these are not automatic for all patients.

  • Antibiotics and Antifungals: Depending on your child’s prior infections, mucosal disease, and the duration of profound neutropenia, the specialist team may consider daily prophylactic options (such as trimethoprim-sulfamethoxazole) [2][7]. However, these drugs can have adverse hematologic effects.
  • Do not start, stop, or change a prophylaxis regimen independently. Prophylaxis decisions must weigh local resistance, allergies, and drug toxicity, and they never replace the need for urgent assessment and empiric treatment of a fever.

Aggressive Oral and Dental Care

One of the most significant and early symptoms of JAGN1-SCN is severe periodontal disease (gum disease). Without aggressive care, children can experience painful gum swelling, bleeding, and the premature loss of both baby and permanent teeth [8][2].

Your daily and long-term dental strategy should include:

  1. Meticulous Hygiene: Daily brushing and very gentle flossing are essential to reduce the bacteria that cause inflammation [9]. Your dentist may also recommend specialized antimicrobial mouthwashes [10].
  2. Frequent Specialist Exams: Children with JAGN1-SCN should see a pediatric dentist or periodontist more often than typical—often every 3 to 4 months—to monitor for early signs of gum recession or bone loss [11][9].
  3. Individualized Procedure Planning: Dental antibiotic prophylaxis is not automatic for every neutropenic child or every routine cleaning. It depends on the current ANC and other blood counts, the invasiveness of the procedure, active oral infection, and the specific hematology–dentistry plan [8]. Ensure your dentist consults directly with your hematology team before procedures.

Long-Term Surveillance

Even when your child is stable on G-CSF, regular check-ups are vital. Standard care includes:

  • Yearly Bone Marrow Biopsies: This allows doctors to check the “factory” for any signs of MDS (myelodysplastic syndrome) or other cellular changes [1].
  • Growth Tracking: Because some JAGN1 variants are associated with shorter stature, your pediatrician will closely monitor your child’s height and weight [12].
  • Spleen Monitoring: Long-term G-CSF use can sometimes cause the spleen to enlarge (splenomegaly), which your doctor may check for during physical exams [7].

Common questions in this guide

What is the main treatment for JAGN1-related severe congenital neutropenia?
The main medical treatment is G-CSF, a daily injection that signals the bone marrow to make more neutrophils. Children with JAGN1-related disease may need higher doses than people with other forms of severe congenital neutropenia, and the care team adjusts treatment according to infections, blood counts, bone marrow findings, and side effects.
Why might G-CSF work less well in a child with JAGN1-SCN?
JAGN1 mutations can be associated with a limited response to G-CSF, so the neutrophil count may not rise enough even when higher doses are used. If serious infections continue despite an optimized treatment plan, the hematology team may discuss a bone marrow transplant evaluation.
Does every child with JAGN1-SCN need preventive antibiotics or antifungals?
No. Preventive antibiotics or antifungal medicines are considered individually based on infection history, mouth or gum disease, the severity and duration of low neutrophil counts, allergies, resistance, and medication risks. Families should not start, stop, or change these medicines without the child's specialist team, and they do not replace urgent evaluation for fever.
How can families protect a child’s teeth and gums with JAGN1-SCN?
Daily brushing and very gentle flossing help reduce bacteria and gum inflammation, and a dentist may recommend an antimicrobial mouthwash. Regular visits with a pediatric dentist or periodontist, often every three to four months, help detect gum disease early. Antibiotics before dental procedures are not automatic and should be planned jointly by the dental and hematology teams.
What monitoring is needed during long-term treatment?
The care team monitors blood counts and the response to G-CSF, while regular follow-up may include yearly bone marrow biopsies, growth measurements, and checks for an enlarged spleen. The timing of blood tests and other evaluations is individualized according to the child's treatment response and infection history.
When might a bone marrow transplant be considered for JAGN1-SCN?
A transplant consultation may be considered when a child has serious infections despite an optimized G-CSF plan or when the bone marrow does not respond adequately to treatment. The hematology team weighs infection frequency, blood counts, marrow findings, treatment effects, and the child's overall health before recommending next steps.

Get notified when new evidence is published on Severe congenital neutropenia due to JAGN1 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (12)
  1. 1

    Severe congenital neutropenias.

    Skokowa J, Dale DC, Touw IP, et al.

    Nature reviews. Disease primers 2017; (3()):17032 doi:10.1038/nrdp.2017.32.

    PMID: 28593997
  2. 2

    Chronic neutropenia: how best to assess severity and approach management?

    Donadieu J, Frenz S, Merz L, et al.

    Expert review of hematology 2021; (14(10)):945-960 doi:10.1080/17474086.2021.1976634.

    PMID: 34486458
  3. 3

    Case report: Granulocyte-macrophage colony-stimulating factor sargramostim did not rescue the neutrophil phenotype in two patients with JAGN1-mutant severe congenital neutropenia.

    Farmand S, Aydin SE, Wustrau K, et al.

    Frontiers in immunology 2024; (15()):1373495 doi:10.3389/fimmu.2024.1373495.

    PMID: 39286252
  4. 4

    Extended clinical phenotypes and treatment modalities in 32 JAGN1-deficient patients: a multicenter study by ESID and EBMT IEWP.

    Fekadu-Siebald J, Salzmann-Manrique E, Heusel JR, et al.

    Blood advances 2025; (9(7)):1702-1711 doi:10.1182/bloodadvances.2024014344.

    PMID: 39775668
  5. 5

    CRISPR/Cas9-mediated ELANE knockout enables neutrophilic maturation of primary hematopoietic stem and progenitor cells and induced pluripotent stem cells of severe congenital neutropenia patients.

    Nasri M, Ritter M, Mir P, et al.

    Haematologica 2020; (105(3)):598-609 doi:10.3324/haematol.2019.221804.

    PMID: 31248972
  6. 6

    Efficacy and Safety of Pegfilgrastim in Patients With Severe Congenital Neutropenia.

    Movahedi M, Moradi L, Alizadeh Z, et al.

    EJHaem 2025; (6(6)):e70198 doi:10.1002/jha2.70198.

    PMID: 41384228
  7. 7

    Recurrent bacterial infections, but not fungal infections, characterise patients with ELANE-related neutropenia: a French Severe Chronic Neutropenia Registry study.

    Rotulo GA, Plat G, Beaupain B, et al.

    British journal of haematology 2021; (194(5)):908-920 doi:10.1111/bjh.17695.

    PMID: 34340247
  8. 8

    Manifestation of severe congenital neutropenia in the oral cavity. Case report.

    Krasuska-Sławińska E, Klaudel-Dreszler M, Minota M, et al.

    Central-European journal of immunology 2013; (48(1)):70-74 doi:10.5114/ceji.2023.125312.

    PMID: 37206584
  9. 9

    Protein Network Alterations in G-CSF Treated Severe Congenital Neutropenia Patients and Beneficial Effects of Oral Health Intervention.

    Bao K, Silbereisen A, Grossmann J, et al.

    Proteomics. Clinical applications 2024; (18(6)):e202400064 doi:10.1002/prca.202400064.

    PMID: 39096313
  10. 10

    Oral health management in children with severe congenital neutropenia with periodontitis: Case report.

    Tao SY, Yao M, Dong YL, et al.

    Medicine 2024; (103(30)):e39086 doi:10.1097/MD.0000000000039086.

    PMID: 39058847
  11. 11

    Evaluation of periodontal status and cytokine/chemokine profile of GCF in patients with severe congenital neutropenia.

    Acar B, Cagdas D, Tan Ç, et al.

    Odontology 2021; (109(2)):474-482 doi:10.1007/s10266-020-00565-1.

    PMID: 33159599
  12. 12

    Phenotypic Variability Associated with Jagunal Homolog 1 (JAGN1) Deficiency Caused by the c.63G>T Variant.

    Pantea CL, Bataneant M, Zimbru CG, et al.

    International journal of molecular sciences 2026; (27(4)) doi:10.3390/ijms27041735.

    PMID: 41751872

This page is for informational purposes only and does not constitute medical advice. Your child's hematology and dental teams should individualize G-CSF, infection, fever, and procedure plans.